Phase I Clinical Trial of CA-4948 (Emavusertib) in Combination With FOLFOX Plus Bevacizumab as Frontline Treatment in Patients With Metastatic Colorectal Cancer

This phase I trial studies the side effects and best dose of CA-4948 when given together with fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). CA-4948 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The chemotherapy drugs used in FOLOX, fluorouracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin is used with fluorouracil to treat colorectal cancer. Bevacizumab is in a class of medications called anti-angiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of the tumor. Giving CA-4948 with FOLFOX plus bevacizumab may be safe, tolerable and/or effective in treating patients with metastatic colorectal cancer.

开始日期2026-01-23

申办/合作机构

National Cancer Institute

NCT05296005

/ Withdrawn临床1期IIT

Total Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction (GEJ) and Gastric Cancers: A Pilot Trial

This phase I trial tests the safety, side effects studies chemotherapy followed by chemotherapy at the same time as radiation therapy (chemoradiation) before surgery (neoadjuvant) in treating patients with stage gastric (stomach) or gastroesophageal junction cancer . Chemotherapy drugs, such as docetaxel, oxaliplatin , leucovorin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy and chemoradiation before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.

开始日期2025-12-31

申办/合作机构

Ohio State University Comprehensive Cancer Center

NCT06780111

/ Not yet recruiting临床1/2期

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This study will look at ESCC that is either locally advanced unresectable, which means it has spread into tissue near where it started and cannot be completely removed by surgery, or metastatic, which means it has spread to other body parts.
Available treatments for these types of ESCC include pembrolizumab and chemotherapy. Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing.
Researchers want to learn about giving pembrolizumab and ifinatamab deruxtecan (I-DXd), a study medicine, with or without chemotherapy to treat ESCC. I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells.
The main goal of this study is to learn about the safety of I-DXd and pembrolizumab with or without chemotherapy and if people tolerate them. Researchers also want to learn how cancer responds (gets smaller or goes away) to the study treatments.

开始日期2025-08-07

申办/合作机构

Merck Sharp & Dohme LLC

[+1]

100 项与奥沙利铂相关的临床结果

登录后查看更多信息

100 项与奥沙利铂相关的转化医学

登录后查看更多信息

100 项与奥沙利铂相关的专利（医药）

登录后查看更多信息

22,033

项与奥沙利铂相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States

Article

作者: Li, Jia ; Mahmoudjafari, Zahra ; Masaquel, Anthony ; Parisé, Hélène ; Bercaw, Eric ; Bognar, Katalin ; Wang, Si-Tien

BACKGROUND:

Glofitamab is a T-cell engaging bispecific monoclonal antibody that was granted accelerated approval from the United States Food and Drug Administration for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after ≥2 lines of systemic therapy (3L+).

METHODS:

A budget impact model was developed for a hypothetical blended commercial/Medicare health plan with 1,000,000 members. Comparators were axicabtagene ciloleucel (Axi-cel), lisocabtagene maraleucel (Liso-cel), tisagenlecleucel (Tisa-cel), loncastuximab tesirine, polatuzumab vedotin + bendamustine + rituximab, rituximab + gemcitabine + oxaliplatin, tafasitamab + lenalidomide, and epcoritamab (Epcor). Total costs included those for drugs, wastage, administration, grade ≥3 adverse reactions, and all-grade cytokine release syndrome) and routine care. Market shares were based on internal projections and expert opinions. Total and per-member per-month (PMPM) net budget impacts over 3 years were calculated.

RESULTS:

Approximately nine patients were projected to be eligible for 3L + DLBCL treatment in a health plan of 1,000,000 members. The introduction of glofitamab as a treatment option resulted in estimated total and PMPM cost savings of $728,697 and -$0.0202, respectively, over 3 years. Costs were reduced across all cost categories but particularly in drug costs. Among the newer therapies, total 3-year cost per treated patient was lowest for glofitamab: $226,658 versus Tisa-cel = $564,113; Axi-cel = $540,002; Liso-cel = $516,272; and Epcor = $335,293. Across all sensitivity analyses, the inclusion of glofitamab had minimal PMPM budget impact, ranging from -$0.0256 to -$0.0108.

CONCLUSIONS:

With the lowest 3-year total cost per treated patient among the newer therapies, glofitamab being an available option in the 3L + DLBCL market is estimated to save a hypothetical 1,000,000-member health plan $728,697 in cumulative total costs and $0.0202 in PMPM costs over 3 years.

2025-12-31·RENAL FAILURE

Knowledge mapping and visualized analysis of research progress in onconephrology: a bibliometric analysis

Article

作者: Wang, Wei ; Wang, Yiwei ; Fan, Shuling

OBJECTIVES:

Onconephrology is an expanding subspecialty focused on the management of cancer patients with renal injury. This study used a comprehensive bibliometric analysis to emphasize the need for cooperation between oncologists and nephrologists, exploring current trends and future research areas in onconephrology.

METHODS:

Relevant literature on onconephrology published between 1 January 2000 and 27 April 2024 was retrieved from the Science Citation Index Expanded of the Web of Science Core Collection, followed by manual screening. Bibliometric analyses were performed using CiteSpace, VOSviewer, and Bibliometrix software.

RESULTS:

A total of 1,853 publications, including 1,647 articles and 206 reviews, by 11,606 authors from 2,757 institutions in 73 countries, were analyzed. Annual publications generally follow a steadily increasing trend, ranging from 25 to 161 documents. The United States (n = 464), The University of Texas MD Anderson Cancer Center (n = 39), Meletios A. Dimopoulos (n = 21), and Nephrology Dialysis Transplantation (n = 35) were the most productive country, institution, author, and journal, respectively. Immune checkpoint inhibitors, glomerular filtration rate, and cisplatin were clusters of highly cited references after 2015. Oxaliplatin, calcium, open-label, and thrombotic microangiopathy were trending topics after 2020. Outcome, acute kidney injury, immunotherapy, and chronic kidney disease were keyword bursts that persisted through 2024.

CONCLUSION:

Current research of onconephrology is focusing on chemotherapeutic nephrotoxicity, kidney function assessment, dosing of chemotherapeutic agents in chronic kidney disease, glomerular disease in cancer, immunotherapy, and electrolyte disturbances. Future directions in this field include clinical trials and thrombotic microangiopathy.

2025-12-01·Journal of Gastrointestinal Cancer

Development of a Prognostic Nomogram for Overall Survival in Gastric Cancer Patients Who Underwent Adjuvant Chemoradiotherapy

Article

作者: Avci, Hanife ; Ozyurek, Yasin ; Hurmuz, Pervin ; Yilmaz, Melek Tugce ; Yigit, Ecem ; Dag, Osman ; Cengiz, Mustafa

PURPOSE:

The aim of this study was to identify prognostic factors influencing overall survival (OS) in patients with gastric cancer treated with adjuvant chemoradiotherapy (CRT) and to develop a predictive model.

METHODS:

We retrospectively evaluated 245 non-metastatic gastric cancer patients who received adjuvant CRT or radiotherapy from 2010 to 2020. Survival analyses were performed using the Kaplan-Meier method. Prognostic factors were identified through univariate and multivariate Cox regression analyses. A nomogram was constructed based on significant predictive factors for OS, including lymph node ratio, T classification, tumor location, and local recurrence.

RESULTS:

The median follow-up duration was 41.5 months (range, 6-144.8 months). The 2- and 5-year OS and progression-free survival were 77% and 53% and 64% and 49%, respectively. In multivariate analysis, tumor location (distal vs. proximal), pT classification (pT1-2 vs. pT3-4), lymph node ratio (< 0.18 vs. ≥ 0.18), and presence of local recurrence were independent prognostic factors for OS. The optimal cut-off value for the total nomogram score predicting OS was 116 points. Patients with < 116 points had 2- and 5-year OS rates of 87% and 73%, respectively, compared to 67% and 30% for those with ≥ 116 points.

CONCLUSION:

A nomogram was constructed incorporating lymph node ratio, T classification, tumor site, and local recurrence for gastric cancer patients receiving adjuvant CRT. Patients with a total score below 116 demonstrated higher survival rates. This nomogram may aid in defining optimal follow-up intervals.

1,405

项与奥沙利铂相关的新闻（医药）

9 小时之前

·今日头条

NK细胞疗法助胃癌患者无病生存近4年，点亮免疫治疗新希望

胃癌（GC）是全球最常见的恶性肿瘤之一，手术仍是可切除胃癌的主要治疗手段，术后化疗作为推荐的辅助治疗方案，已被多项研究证实可改善患者预后。然而，30%~50%的患者在手术及辅助化疗后5年内仍会出现复发。印戒细胞癌（SRC）作为胃癌的特殊亚型，因癌细胞胞质内充满黏液、细胞核被挤压至一侧呈“印戒”状而得名。其恶性程度极高，虽早期患者预后优于其他胃癌亚型，但晚期患者预后甚至差于未分化腺癌。由于SRC肿瘤的R0切除率较低，且对化疗敏感性显著低于非SRC肿瘤，临床上对新型术后辅助治疗的需求尤为迫切。自然杀伤（NK）细胞无需预先致敏即可诱导细胞毒性的独特特性，使其成为免疫治疗的理想选择。《Medicine》杂志曾报道一则经典案例：一位晚期胃印戒细胞癌（SRC）患者经NK细胞辅助治疗联合手术及化疗后，实现了长达46个月的无病生存。这一突破首次以临床实例证实了NK细胞辅助治疗在晚期胃印戒细胞癌中的显著价值！相信随着免疫治疗研究的不断深入，像NK细胞这样的创新疗法将为更多晚期癌症患者点燃生命的希望！ ▲截图源自“Medicine” 化疗耐药不再绝望！NK细胞联合治疗让胃印戒细胞癌患者，无病生存3.8年，肿瘤标志物恢复正常《Medicine》报道的这个临床案例，是一位41岁女性患者，确诊为胃窦小弯侧溃疡性低分化腺癌（以印戒细胞癌为主，伴少部分黏液腺癌），肿瘤大小7×6×1.8cm，侵犯胃壁全层，脉管内见癌栓，胃大弯侧部分淋巴结转移，术后病理分期为ⅢC期（T4a，N3a，M0），行根治性（R0）胃切除术后，接受6个周期奥沙利铂为基础的化疗方案。治疗初期，患者糖类抗原（CA）72-4水平显著下降，但随化疗推进，CA72-4快速升高至86.34U/mL，且免疫功能检测显示CD3⁺T细胞及NK细胞百分比均降低，提示免疫功能受损。2016年11月起，患者接受NK细胞免疫治疗（静脉注射，每年3次）。结果显示： NK细胞治疗后，患者肿瘤标志物检测及腹部CT扫描均恢复正常，CA72-4水平逐步降至正常范围。截至最后一次随访，患者已实现46个月（≈3.8年）无病生存，且状态良好，未见疾病进展迹象（详见下图）。 ▲图源“Medicine”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除小编寄语总之，上述这一临床实践表明，NK细胞免疫治疗或为晚期胃印戒细胞癌患者提供新的治疗选择，有望为改善这类难治性肿瘤的预后带来突破性进展。不过，全球肿瘤医生网小编也需要提醒广大患者，癌症作为一种高度突变且极度狡猾的疾病，目前很难仅依靠单一疗法，达到预期治疗效果。现阶段理想的抗癌治疗，是依托于权威医院和权威专家的早期规范诊断，并在传统治疗（如手术、放化疗）的基础上，根据患者自身情况、疾病特点、经济状况等，辅以免疫细胞疗法（如NK、CAR-T、TCR-T、TIL、CAR-NK细胞疗法）、癌症疫苗、靶向药物、硼中子俘获疗法、质子治疗等抗癌新药/新技术，以预防癌症复发或转移、尽可能延长生存期、提高患者的生存质量。参考资料 [1]Jin YY,et al.NK cells adjuvant therapy shows survival benefits in a gastric mixed signet ring cell carcinoma patient: A case report. Medicine (Baltimore). 2021 Mar 12;100(10):e24979. https://journals.lww.com/md-journal/fulltext/2021/03120/nk_cells_adjuvant_therapy_shows_survival_benefits.61.aspx 本文为全球肿瘤医生网原创，未经授权严禁转载

细胞疗法免疫疗法临床结果

17 小时之前

·Insight数据库

全球首款 CD79B ADC 新适应症国内申报上市

5 月 28 日，CDE 官网显示，罗氏注射用维泊妥珠单抗（商品名：Polivy、优罗华）新适应症上市申请获受理。此前 2023 年 1 月，该产品已在中国获批两项适应症。来源：CDE 官网维泊妥珠单抗是罗氏开发的一款靶向 CD79B 的 ADC，2019 年 6 月以加速批准的方式在美国获批上市，联合苯达莫司汀+利妥昔单抗用于既往至少接受过 2 种治疗方案的 R/R DLBCL，目前已转为完全批准。2023 年 4 月，该产品 DLBCL 适应症被拓展至一线。2023 年 1 月，维泊妥珠单抗进入中国市场，适应症为：1）联合利妥昔单抗、环磷酰胺、多柔比星和泼尼松适用于治疗既往未经治疗的 DLBCL 成人患者；2）联合苯达莫司汀和利妥昔单抗用于不适合接受造血干细胞移植的 R/R DLBCL 成人患者。今年 4 月，罗氏在一季度报中披露，2025 年将递交维泊妥珠单抗联合莫妥珠单抗（CD20/CD3 双抗）二线以上 DLBCL 适应症的上市申请。来源：罗氏财报作为全球唯一一款获批的 CD79B ADC，维泊妥珠单抗自上市以来，销售额一路高歌猛进，24 年成功跻身重磅炸弹行列。25 年第一季度，该产品销售额为 3.58 亿瑞士法郎，同比增长 42%。来源：Insight 数据库Insight 数据库显示，目前全球仅有 4 款 CD79B ADC 在研，除维泊妥珠单抗外，还有恒瑞 SHR-A1912（III 期）以及新港生物 NBT508（I 期）已进入临床阶段。来源：Insight 数据库今年 5 月，恒瑞在 ASCO 大会上公布了 SHR-A1912 与利妥昔单抗、吉西他滨和奥沙利铂 (R-GemOx) 联合治疗 R/R DLBCL 的 Ib/II 期临床数据。结果显示，1.8 mg/kg SHR-A1912 与 R-GemOx 联合用药耐受性良好，且安全性与其各成分一致。该联合用药表现出强大的抗肿瘤活性，具有快速且持久的疗效。封面来源：企业logo免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：月牙PR 稿对接：微信 insightxb投稿：微信 insightxb；邮箱 insight@dxy.cn

财报抗体药物偶联物ASCO会议上市批准临床1期

2025-05-27

·今日头条

TIL疗法助4期肠癌患者生存近2年，同类疗法剑指宫颈癌、胰腺癌等

据《今日美国》（TODAY）官网报道，一位36岁的晚期结肠癌患者E女士，在23岁从艺术学院毕业时被确诊为晚期结肠癌，生活从此发生剧变。接下来的十年间，她尝试了手术、化疗、放疗和常规免疫疗法等多种治疗手段，病情却始终未得到控制，甚至一度被医生告知可能活不过30岁。然而，12年后，在经历多轮放化疗失败后，一项关键的临床试验挽救了她的生命——她在接受明尼苏达大学开展的基于CRISPR技术的新型TIL细胞治疗后，病情迅速好转并实现完全缓解（CR），体内已完全检测不到肿瘤痕迹。这一突破性病例在近期芝加哥举行的美国癌症研究协会（AACR）年会上被公开报告，研究团队将临床试验结果同步发表于《柳叶刀・肿瘤学》杂志，更是引发全球医学界的广泛关注。 E女士的重生不仅是个人生命的奇迹，更彰显了医学科技突破的力量，为癌症患者点燃了"绝处逢生"的勇气，让我们期待更多医学奇迹照亮生命，让每一个被病魔笼罩的灵魂，都能重遇属于自己的阳光！ ▲截图源自“TODAY” 当传统治疗穷途末路时，CRISPR-Cas9编辑TIL疗法让晚期结肠癌患者完全缓解，无癌生存近两年 2013年，23岁的E女士因剧烈胃痉挛就医，血液检测显示血红蛋白水平异常，经系列检查确诊为III期结直肠癌，结肠内发现两处肿瘤病灶。她接受肿瘤切除手术及为期一年的化疗，虽大部分癌细胞被清除，但少量癌细胞扩散至腹膜，病情进展为IV期。2016年，因癌细胞侵袭生殖系统周围组织，艾玛接受了部分子宫切除术。此后十年间，她尝试化疗、放疗、免疫疗法及实验性治疗（如腹腔热灌注化疗HIPEC），但病情仍缓慢进展，并多次因治疗并发症而接受手术，甚至需暂时性回肠造口术辅助康复。 2022年底，E女士获悉明尼苏达大学EmilLou教授团队主导的一项新型肿瘤浸润淋巴细胞（TIL）疗法的临床试验。该疗法通过CRISPR-Cas9技术（被形象的称为“基因剪刀”），敲除T细胞中的CISH基因——这个曾被认为“无药可治”的免疫检查点，使改造后的T细胞更精准识别并攻击癌细胞，突破肿瘤免疫逃逸机制。她于2022年底完成白细胞采集用于个性化治疗，并在2023年3月先接受五天“强化化疗”，随后输注经基因编辑的自体TIL细胞。这项I期临床试验（NCT04426669），共纳入12例其他疗法失败的IV期结直肠癌患者。结果显示： 50%的（6例）患者于TIL细胞治疗第28天实现病情稳定（SD），其中 4例（33%）病情稳定状态持续至56天。中位无进展生存期（PFS）达到57天（范围：25-156天，详见下图A），中位总生存期（OS）更是长达129天（范围：46-290天，详见下图C）。 ▲图源“AACR”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除其中，E女士的治疗结果是迄今为止是最令人惊喜的，她在TIL细胞治疗1个月后，肿瘤迅速缩小；两个月后，所有影像学检查均未发现癌细胞，达到临床完全缓解（CR）。且在近两年（21个月）的随访期间病情持续稳定，这在IV期结直肠癌中“几乎闻所未闻”，通常仅有不足10%的晚期患者能达到如此深度缓解。她从“无法治愈”到“无癌生存”的转变，为免疫治疗开辟了新方向，团队正基于这一突破优化疗法，以期惠及更多患者。如今35岁的E女士已重返插画师岗位，她感慨：“癌症教会我关注身体信号、重视家族筛查，更让我懂得活在当下的珍贵”。她的经历不仅是个人生命的奇迹，更印证了科学与生命韧性碰撞出的希望——当基因编辑技术突破传统治疗瓶颈，希望终将划破黑暗！ ▲图源“AOL”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 TIL疗法在晚期黑色素瘤中展现出长期疗效，4年OS率达47.3% 在2023年欧洲肿瘤内科学会（ESMO）年会上，自体肿瘤浸润淋巴细胞（TIL）疗法Lifileucel（LN-144）治疗晚期黑色素瘤的Ⅱ期C-144-01试验（NCT02360579）公布了一组惊艳数据：该疗法在经检查点抑制剂治疗失败的晚期黑色素瘤患者中，展现出具有临床意义的抗肿瘤活性及早期、持久的应答效果。研究对153例患者进行了4年随访，结果显示：独立审查委员会（IRC）评估的客观缓解率（ORR）为31.4%，部分缓解（PR）及以上疗效患者的中位最佳缓解时间为1.5个月（范围：1.3-30.4个月），最长缓解持续时间达55.8个月，且 4例患者在治疗1年多后从部分缓解转为完全缓解（CR）。全体患者的中位总生存期（OS）为13.9个月（95%CI，10.6-17.8个月）， 4年OS率达47.3% （95%CI，32.5%-60.7%），这也意味着近半数患者存活超4年。 ▲截图源自“onclive” 难治性实体瘤迎曙光：TIL疗法暴击胰腺癌、结直肠癌、卵巢癌，1例患者生存超4年近日，美国MD安德森癌症中心公布了一项针对多癌种的TIL疗法临床试验数据，该研究纳入了传统治疗无效的8例转移性结直肠癌（CRC）、5例胰腺癌（PDAC）、3例卵巢癌（OVCA）患者，数据令人振奋。结果显示：全部入组患者的疾病控制率（DCR）高达62.5% （95%CI：35.4%~84.8%），即超六成患者的病情得到有效控制。治疗12周时病情稳定率（SD）达31.3% （5例），显示疗法早期对部分患者具有稳定肿瘤的作用。此外，中位总生存期（OS）达18.86个月，中位无进展生存期（PFS）为2.53个月，突破了这类难治性肿瘤的传统生存预期。 ▲图源“J Immunother Cancer”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除值得一提的是，一名晚期胰腺癌患者在接受TIL疗法后，疾病稳定状态持续17个月。后续她继续接受了单药派姆单抗治疗及两种I期临床试验疗法（RAD51抑制剂与针对体细胞ARID1A突变的药物AZD6738），至今已存活超4年，成为该研究中极具代表性的长期生存案例。 ▲图源“J Immunother Cancer”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除这项研究表明，TIL疗法在结直肠癌、胰腺癌、卵巢癌等“难治性实体瘤”中展现出跨癌种的临床活性，尤其为传统治疗手段有限的患者提供了新的生存希望。 10周肿瘤全消！TIL联合PD-1疗法让复发性宫颈癌患者实现“临床治愈” 全球知名期刊《BMJJournals》曾报道过一个“复发性宫颈癌患者，在TIL细胞治疗后达完全缓解”的惊艳案例（NCT04766320）。该患者是一位52岁女性，2019年5月确诊为IB3r期宫颈癌，遂接受根治性子宫切除术+盆腔淋巴结清扫术，术后病理分期升级为IIIC1p期（盆腔淋巴结受累）。随后接受了4个周期的紫杉醇脂质体+奥沙利铂化疗。然而17个月后，核磁共振成像（MRI）显示膀胱疾病复发，遂接受部分膀胱切除术，术后继续辅助化疗，并保留肿瘤切除物用于TIL细胞制备。患者入组后，现接受环磷酰胺静脉给药，之后接受TIL细胞静脉输注，并后续联合PD-1抗体治疗。治疗效果显著：TIL输注6周后，T1WI影像显示病灶显著缩小（黄色箭头）；首次评估（输注后42天）显示，患者无发热、体重减轻，体格检查未触及浅表淋巴结肿大；依据RECISTv1.1标准，输注10周后确认达到完全缓解（CR ，详见下图）。 ▲图源“BMJ journals”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除小编寄语 TIL细胞疗法是在患者自身的肿瘤组织中，培养扩增抗癌利器，将肿瘤组织“变废为宝”，在治疗实体瘤领域具有独特优势，甚至能帮助部分实体瘤患者实现长期带瘤生存！好消息是，目前我国多款TILs疗法已正式获批开展临床研究，主要针对非小细胞肺癌、食道癌、胆管癌、乳腺癌、卵巢癌、宫颈癌等多款实体瘤。我国TILs疗法是在美国的肿瘤浸润淋巴细胞（TIL）疗法的基础上，经过特殊改良，以增加TIL细胞的自我扩增能力，克服肿瘤微环境，回输到患者体内后，对癌细胞进行猛烈攻击。参考资料 [1]Amaria R,et al.Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 2;12(2):e006822. https://pmc.ncbi.nlm.nih.gov/articles/PMC10840042/ [2]Guo J,et al.Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen[J]. Journal for Immunotherapy of Cancer, 2022, 10(2): e003887. https://jitc.bmj.com/content/10/2/e003887 [3]https://www.today.com/health/news/colon-cancer-crispr-cish-immunotherapy-rcna203485 [4]https://www.onclive.com/view/lifileucel-demonstrates-long-term-efficacy-and-survival-benefit-in-advanced-pretreated-melanoma 本文为全球肿瘤医生网原创，未经授权严禁转载

免疫疗法细胞疗法基因疗法AACR会议临床3期

100 项与奥沙利铂相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01790	奥沙利铂	L01XA03	DB00526

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
小肠癌	日本	Takata Pharmaceutical Co. Ltd.	2018-09-21
小肠癌	日本	Yakult Honsha Co., Ltd.	2018-09-21
胃癌	日本	Takata Pharmaceutical Co. Ltd.	2015-03-20
胃癌	日本	Yakult Honsha Co., Ltd.	2015-03-20
胰腺癌	日本	Yakult Honsha Co., Ltd.	2013-12-20
胰腺癌	日本	Takata Pharmaceutical Co. Ltd.	2013-12-20
结直肠癌	美国	Sanofi-Aventis U.S. LLC	2007-01-10
晚期结直肠腺癌	澳大利亚	Medis Pharma Pty Ltd.	2006-11-28
结肠癌	美国	Sanofi-Aventis U.S. LLC	2002-08-09
直肠癌	美国	Sanofi-Aventis U.S. LLC	2002-08-09
肿瘤	中国	南京制药厂有限公司	2000-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
弥漫性大B细胞淋巴瘤	临床3期	美国	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	中国	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	澳大利亚	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	比利时	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	丹麦	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	法国	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	德国	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	波兰	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	西班牙	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	瑞士	Hoffmann-La Roche, Inc.	2021-02-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AACR2025	N/A	结直肠癌	-	Obatoclax	淵壓遞鏇觸鹹觸衊壓醖(鹽鑰憲夢獵繭簾夢鹽衊) = 選願繭醖觸顧窪蓋獵選網網蓋獵製壓獵壓遞餘 (糧願餘壓簾壓醖範膚遞 )	积极	2025-04-27
NCT03861702 (BTCRC-GI15-067, CTgov)	临床2期	局部晚期胰腺腺癌	28	LEUCOVORIN CALCIUM+Liposomal Irinotecan+Oxaliplatin+Fluorouracil	窪鏇壓齋遞獵廠憲網鏇 = 蓋積簾願構願簾餘醖壓願築遞鑰築鹽觸鏇餘鏇 (構繭獵選網鬱鏇餘遞壓, 構鏇蓋窪淵鹹衊餘選簾 ~ 簾鑰鏇製鹹衊壓餘顧遞) 更多	-	2025-04-18
NCT04380337 (SHORT-FOX, CTgov)	临床2期	直肠癌 \| 直肠腺癌	38	IMRT+LEUCOVORIN CALCIUM+irinotecan+oxaliplatin+capecitabine+Fluorouracil	廠艱艱蓋衊顧淵糧築糧 = 鬱艱夢壓鑰鬱衊選鬱淵範網膚壓選糧繭齋餘夢 (鏇顧鏇窪鏇築遞夢衊餘, 網範蓋網獵繭願遞蓋糧 ~ 夢餘選構遞艱壓鬱衊餘) 更多	-	2025-02-25
JPRN-UMIN000013036 (ACHIEVE-2, ASCO_GI2025)	临床3期	结肠癌辅助	525	3-month mFOLFOX6/CAPOX treatment	膚壓鏇鬱窪窪鹹遞積齋(蓋衊鬱積範餘淵蓋製淵) = The incidence of long-lasting PSN was significantly lower at 3 months than at 6 months of therapy 範淵鏇齋醖選願製衊製 (壓構願衊網艱憲簾網鑰 ) 更多	积极	2025-01-23
				6-month mFOLFOX6/CAPOX treatment
JPRN-jRCTs031200094 (ASCO_GI2025)	临床2期	食管鳞状细胞癌新辅助	54	Neoadjuvant FLOT therapy	築壓鹹觸齋構鬱齋艱願(淵憲蓋膚夢獵廠鹽遞簾) = 鬱餘壓衊夢鏇鏇範衊製構範襯膚鹹範淵繭範膚 (糧廠醖選選願鑰範範蓋, 29.8 ~ 57.7) 更多	积极	2025-01-23
JPRN-UMIN000022210 (Phase I/II clinical trial of preoperative docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for esophagogastric junction adenocarcinoma, ASCO_GI2025)	临床1/2期	胃食管交界处腺癌新辅助 \| 辅助	40	Docetaxel 60 mg/m²	簾遞鏇蓋齋憲糧築遞網(憲鏇艱遞顧繭醖鹹積選) = 襯顧顧構襯繭夢顧鏇糧鑰簾糧蓋鹽觸鹹襯艱網 (壓鏇築醖簾獵鑰淵憲廠 ) 更多	积极	2025-01-23
				S-1 120 mg/body	獵壓憲淵範選艱選衊獵(鑰鏇壓鏇積蓋願鹹簾遞) = 齋齋鑰鬱艱鑰顧廠鹽蓋選範壓簾鬱鑰簾簾鑰築 (遞鬱窪網鬱鏇願顧網積 ) 更多
NCT05627635 (ASCO_GI2025)	临床1期	微卫星稳定型结直肠癌 MSS	14	Folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B)	餘鹹觸蓋衊醖憲淵齋壓(窪網艱範觸製簾積壓顧) = one pt at DL1 with transient G3 AST/ALT elevation and transient G2 colitis (resolved with steroids and infliximab), one pt at DL1 with G2 hypothyroidism and one patient at DL2 with G2 hyperthyroidism 範簾衊積選膚顧艱觸繭 (遞艱遞襯襯淵糧觸簾憲 ) 更多	积极	2025-01-23
ASCO_GI2025	N/A	晚期肝细胞癌一线	-	Lenvatinib plus FOLFOX-HAIC	選衊廠糧鑰製顧築積壓(壓鑰鏇觸糧遞艱憲夢夢) = Grade 3-4 adverse events, including nausea, vomiting, diarrhea, thrombocytopenia, and neutropenia, were more prevalent in the lenvaHAIC group 窪壓夢選憲夢觸網蓋廠 (鑰遞選鏇齋膚鬱繭製襯 ) 更多	积极	2025-01-23
				Lenvatinib alone
NCT03500874 (HARVEST trial, Pubmed \| Eur J Cancer)	临床3期	结直肠癌肝转移辅助 RAS/BRAF mutations \| positive postoperative ctDNA methylation	92	Standard systemic chemotherapy only	艱夢艱網繭網觸艱齋選(獵齋願製選願願鬱觸鑰) = 襯築壓鏇膚製簾簾夢餘網築廠膚憲遞築壓觸壓 (淵糧艱築壓衊鬱衊窪壓 )	积极	2025-01-01
				Standard systemic chemotherapy + HAI-FUDR	艱夢艱網繭網觸艱齋選(獵齋願製選願願鬱觸鑰) = 憲顧淵艱鹽遞範鬱齋壓網築廠膚憲遞築壓觸壓 (淵糧艱築壓衊鬱衊窪壓 )